Close Menu

Which sequencing platform will win the race to the 30X, $1,000 genome? That's what Keith Robison at Omics! Omics! wants to know. Of all the existing platforms, two are close to what Robison calls the "arbimagical" goal — a goal which is arbitrary but has achieved a magical aura from being repeated so much. ABI's SOLiD 4 platform has been said to generate a $6,000 genome, and the SOLiD 4 hq upgrade is planned for this fall with a target of delivering a $3,000 genome, Robison says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.